Skip to main content
. 2020 Jul 24;23(8):101408. doi: 10.1016/j.isci.2020.101408

Figure 2.

Figure 2

Patient-Derived Organoids Maintain Identical Patient Morphology and Immunophenotype in Culture

(A) Three distinct FNA patient-derived organoids (FNA-PDOs) for melanoma. These organoids also maintain S-100 and Ki-67 immunohistochemical (IHC) staining similar to the patient tumor (20× magnification; scale bar, 50 μm).

(B) Two distinct FNA-PDOs for thyroid cancer maintain expression of markers indicative of thyroid differentiation, AE1/AE3 and TTF-1, on IHC (20× magnification; scale bar, 50 μm).

(C) Gastrointestinal and renal FNA-PDOs demonstrate preserved AE1/AE3 expression (20× magnification; scale bar, 50 μm).

(D) Immunofluorescence staining of the two thyroid cancer FNA-PDOs (shown in B) highlights both a population of tumor cells (green, CK8/18 positive staining) as well as a supportive population of cancer-associated fibroblasts (CAFs, red, SMA; DNA in blue; 20× magnification; scale bar, 100 μm).

(E) Disc organoid cultures for numerous tumor types tested demonstrate 2D cultures that extend from organoids and grow along the bottom of the plate. Bright-field images of melanoma FNA-PDO taken at 4 and 6 days of culture showing rapid growth of the 2D population (10× magnification; scale bar, 100 μm).

(F) Immunofluorescence of these 2D cultures (thyroid FNA-PDO shown) demonstrates both cancer epithelial cells (CK8/18, green) and cancer-associated fibroblasts (CAFs, SMA, red; 10× magnification; scale bar, 100 μm).